<DOC>
	<DOCNO>NCT02500953</DOCNO>
	<brief_summary>The objective study evaluate safety tolerability single multiple oral dose ASP3325 evaluate effect administration time pharmacodynamics ASP3325 orally administer three time day .</brief_summary>
	<brief_title>A Single Multiple Oral Dose Study Treatment Schedule-finding Study Non-elderly , Healthy Subjects</brief_title>
	<detailed_description>&lt; Part 1 : Single ascend dose &gt; Primary objective - To evaluate safety tolerability single oral dose ASP3325 non-elderly , healthy adult Japanese male female , Caucasian male subject Secondary objective - To evaluate pharmacokinetics pharmacodynamics - To evaluate gender difference pharmacokinetics pharmacodynamics - To evaluate ethnic difference pharmacokinetics pharmacodynamics Japanese Caucasians &lt; Part 2 : Multiple ascend dose &gt; Primary objective - To evaluate safety tolerability multiple oral dos ASP3325 non-elderly , healthy adult Japanese male female subject Secondary objective - To evaluate pharmacokinetics pharmacodynamics - To evaluate gender difference pharmacokinetics pharmacodynamics &lt; Part 3 : Evaluation effect administration time &gt; Primary objective - To evaluate effect administration time pharmacodynamics ASP3325 orally administer three time day different administration timing 30 minute meal , meal , 30 minute meal , 2 hour meal non-elderly , healthy adult Japanese male subject crossover design Secondary objective - To evaluate safety pharmacokinetics</detailed_description>
	<criteria>body weight ( screen ) Japanese male : ≥50.0 kg , &lt; 80.0 kg Japanese female : ≥40.0 kg , &lt; 70.0 kg Caucasian male : ≥50.0 kg , &lt; 100.0 kg BMI ( screen ) Japanese : ≥17.6 kg/m2 , &lt; 26.4 kg/m2 Caucasians : ≥18.5 kg/m2 , &lt; 30.0 kg/m2 Ethnicity Japanese : ( 1 ) The investigator subinvestigator confirm ethnicity base appearance ( skin color : yellow ) fact parent four grandparent race ( lineage ) base interview . ( 2 ) The subject reside outside Japan 5 year longer . Caucasians : ( 1 ) The investigator subinvestigator confirm ethnicity base appearance ( skin color : white brown ) fact parent four grandparent race ( lineage ) base interview . ( 2 ) The subject reside outside subject 's country 5 year longer . Healthy , judge investigator subinvestigator base result medical examination ( subjective symptom objective finding ) test obtain screen period hospitalization immediately administration . Received investigational drug clinical postmarketing study within 120 day screen period screen hospitalization ( Day −2 [ Part 1 ] Day −3 [ Part 2 Part 3 ] ) schedule receive investigational drug . Donated equal 400 mL whole blood within 90 day screen period screen hospitalization ( Day −2 [ Part 1 ] Day −3 [ Part 2 Part 3 ] ) , equal 200 mL whole blood within 30 day , blood component within 14 day screen , schedule donate equal 400 mL whole blood blood component . Received medication , vitamin include vitamin D , supplement include calcium , iron , magnesium , niacin ( nicotinic acid nicotinamide ) , schedule receive medication , within 7 day hospitalization ( Day −2 [ Part 1 ] Day −3 [ Part 2 Part 3 ] ) . A deviation normal range blood pressure , pulse rate , body temperature , standard 12lead electrocardiogram ( ECG ) screen Day −1 . Any deviation follow criterion laboratory test screen Day −1 . The normal range specify study site test/assay organization use normal range clinical study . Hematology : 1 . A deviation +20 % upper limit −20 % low limit normal range . However , WBC within normal range , differential count leukocyte ignore . Biochemistry : 1 . A deviation normal range AST , ALT , Cre , blood glucose , serum electrolyte ( Na , K , Cl , Mg , Ca , P ) . 2 . A deviation +20 % upper limit −20 % low limit normal range parameter . However , low limit normal range establish parameter deviation low limit consider clinically significant ( AST , ALT , γGTP , TBil , DBil , IBil , ALP , LDH , CK , TCho , TG , TBA , BUN , Cre , UA ) . TBA iPTH confirm laboratory test screen . Urinalysis : 1 . A deviation normal range test parameter ( female subject Part 2 menstruate screening may eligible even urinary blood positive ) . Urinary drug abuse test : 1 . A positive result benzodiazepine , cocainebased narcotic , analeptic drug , cannabis , barbituric acid derivative , morphinebased narcotic , phencyclidine , tricyclic antidepressant . Immunological test ( screen ) : 1 . A positive result HBs antigen , HBc antibody , HAV antibody ( IgM ) , HCV antibody , HIV antigen/antibody , syphilis . Pregnancy test : 1 . Female subject test positive pregnancy . Failure meet criterion 12lead ECG QT assessment screening ( Part 1 Part 2 ) . Women may pregnant , lactate mother , woman wish become pregnant study period . Concurrent history drug allergy . Upper gastrointestinal disease ( e.g . nausea , vomit , stomachache ) within 7 day hospitalization ( Day −2 [ Part 1 ] Day −3 [ Part 2 Part 3 ] ) . Concurrent previous hepatic disease ( e.g . viral hepatitis druginduced liver injury ) . Concurrent previous heart disease ( e.g . congestive heart failure , ischemic heart disease , arrhythmia require treatment ) . Concurrent respiratory disease ( e.g . bronchial asthma chronic bronchitis ) previous serious respiratory disease ( except history childhood asthma ) . Concurrent gastrointestinal disease ( e.g . peptic ulcer gastroesophageal reflux esophagitis ) previous serious gastrointestinal disease ( except history appendicitis ) . Previous operation gut excision ( except history appendectomy ) . Concurrent previous renal disease ( e.g . acute renal failure , glomerulonephritis , interstitial nephritis ; except history calculus ) . Concurrent previous endocrine disease ( e.g . hyperthyroid , hypothyroid , abnormality growth hormone ) . Concurrent previous cerebrovascular disorder ( e.g . cerebral infarction ) . Concurrent previous malignant tumor . Excessive drinking smoking habit . [ Measure `` excessive '' ] : Alcohol : ≥45 g/day [ large bottle beer contain 25 g alcohol , 1 gou Japanese sake contain 22 g alcohol ] Smoking : ≥20 cigarettes/day Irregular defecation pattern ( less frequent day ) ( Part 2 Part 3 ) . Unable consume tolerate phosphorus calciumcontrolled meal hospitalization .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>ASP3325</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>